Monoclonal antibodies (mAbs) offer a treatment option for individuals with severe COVID-19 and are especially important in high-risk individuals where vaccination is not an option …
Y Chen, X Zhao, H Zhou, H Zhu, S Jiang… - Nature Reviews …, 2023 - nature.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a recently emerged pathogenic human coronavirus that belongs to the sarbecovirus lineage of the genus …
M McCallum, N Czudnochowski, LE Rosen, SK Zepeda… - Science, 2022 - science.org
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of concern evades antibody-mediated immunity that comes from vaccination or infection with …
The emergence of the highly transmissible B. 1.1. 529 Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is concerning for antibody …
The unprecedented public health and economic impact of the COVID-19 pandemic caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been …
Although most mutations in the severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) genome are expected to be either deleterious and swiftly purged or relatively …
H Qi, B Liu, X Wang, L Zhang - Nature Immunology, 2022 - nature.com
Two and a half years into the COVID-19 pandemic, we have gained many insights into the human antibody response to the causative SARS-CoV-2 virus. In this Review, we …
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the global COVID-19 pandemic. Rapidly spreading SARS-CoV-2 variants may jeopardize newly …
DA Collier, A De Marco, IATM Ferreira, B Meng… - Nature, 2021 - nature.com
Transmission of SARS-CoV-2 is uncontrolled in many parts of the world; control is compounded in some areas by the higher transmission potential of the B. 1.1. 7 variant …